A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Completed · Phase 2 · Has a placebo group

Conditions studied: Metastatic Breast Cancer

In brief

This Phase II, double-blind, randomized, placebo-controlled multicenter study will investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with HER2-positive locally advanced or metastatic BC who have received prior trastuzumab and taxane based therapy, either alone or in combination, and/or who have progressed within 6 months after completing adjuvant therapy.

Key facts

Study ID

NCT02924883

Run by

Hoffmann-La Roche

People needed

202

Starts

2016-09-26

Expected to finish

2020-02-06

Last updated by the study team

2021-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Archival tumor samples must be obtained from primary and/or metastatic sites
• Able to submit tumor tissue that is evaluable for programmed death- ligand 1 (PD-L1) expression
• HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies
• Histologically or cytologically confirmed invasive BC: incurable, unresectable, locally advanced BC previously treated with multimodality therapy or metastatic BC
• Prior treatment for BC in the: adjuvant; unresectable locally advanced; or metastatic settings; which must include both, a taxane and trastuzumab (alone or in combination with another agent)
• Progression must have occurred during or after most recent treatment for locally advanced/metastatic BC or within 6 months after completing adjuvant therapy
• Participants must have measurable disease that is evaluable as per RECIST v1.1
• Eastern Cooperative Oncology Group Performance Status of 0 or 1
• Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause
• Use of highly effective method of contraception as defined by the protocol

You may not qualify if…

• Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists, anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
• Receipt of any anti-cancer drug/biologic or investigational treatment within 21 days prior to Cycle 1 Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1 Day 1; recovery of treatment related toxicity consistent with other eligibility criteria
• Radiation therapy within 2 weeks prior to Cycle 1, Day 1
• History of exposure to the cumulative doses of anthracyclines
• History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or participants who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence
• Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites
• Participants with severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
• Current severe, uncontrolled systemic disease
• Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment
• Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
• Need for current chronic corticosteroid therapy (>=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)
• Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than (>) 2 weeks prior to randomization
• Participants with known central nervous system disease
• Leptomeningeal disease
• History of autoimmune disease
• Prior allogeneic stem cell or solid organ transplantation
• Active tuberculosis
• Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
• Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization
• Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial
• Participants who are breastfeeding, or intending to become pregnant during the study

Where it is running

• University of Colorado — Aurora, Colorado, United States
• MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) — Washington D.C., District of Columbia, United States
• SCRI Florida Cancer Specialists South — Fort Myers, Florida, United States
• Florida Cancer Specialists; Saint Petersburg — St. Petersburg, Florida, United States
• Northside Hospital — Atlanta, Georgia, United States
• Johns Hopkins Univ Med Center — Baltimore, Maryland, United States
• San Juan Oncology Associates — Farmington, New Mexico, United States
• Laura and ISAAC Perlmutter Cancer Center at NYU Langone. — New York, New York, United States
• Ohio State Uni Medical Center — Columbus, Ohio, United States
• Magee Womens Hospital — Pittsburgh, Pennsylvania, United States
• Cancer Care Associates of York — York, Pennsylvania, United States
• SCRI Tennessee Oncology Chattanooga — Chattanooga, Tennessee, United States
• Tennessee Oncology; Sarah Cannon Research Institute — Nashville, Tennessee, United States
• University of Washington — Seattle, Washington, United States
• St George Hospital; Cancer Care Centre — Kogarah, New South Wales, Australia
• Calvary Mater Newcastle — Waratah, New South Wales, Australia
• Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology — Woolloongabba, Queensland, Australia
• Peter MacCallum Cancer Center — East Melbourne, Victoria, Australia
• Peninsula and South Eastern Haematology and Oncology Group — Frankston, Victoria, Australia
• Sunshine Hospital — St Albans, Victoria, Australia
• St John of God Hospital; Bendat Cancer Centre — Subiaco, Western Australia, Australia
• Lakeridge Health Oshawa; Oncology — Oshawa, Ontario, Canada
• The Ottawa Hospital Cancer Centre; Oncology — Ottawa, Ontario, Canada
• Sunnybrook Odette Cancer Centre — Toronto, Ontario, Canada
• Breastlink Med Group Inc — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.